Neovii Pharmaceuticals AG Establishes Global Scientific Department
Neovii continues to strengthen its leadership team and capabilities with the appointment of Richard Sachse as Global Chief Scientific Officer. With the appointment of Dr. Sachse, Neovii has set up a Global Scientific Department which comprises all regulatory, medical, and development activities globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180703005142/en/
Neovii’s CEO Juergen Pohle commented: “By establishing a Global Scientific Department, Neovii makes another step forward to become a leading biopharmaceutical company in the transplantation segment.” He added: “We are very excited that Richard joins Neovii and will establish the new Global Scientific Department. His deep understanding and long-term experience in clinical development and regulatory activities, as well as his know-how and strong leadership skills, make him the right person to push this role forward and to drive the business into our next chapter.” Dr. Sachse will also join Neovii’s Global Leadership Team.
Dr. Sachse previously held the position of Senior Vice President, Chief Scientific Officer, and Chief Medical Officer at Æterna Zentaris. In this role Dr. Sachse succeeded in designing and completing development programs for FDA drug approval. He draws on more than 20 years of experience in the pharmaceutical industry not only at Æterna Zentaris, but also with Boehringer Ingelheim, UCB, Schwarz Biosciences, Peptor, and Bayer.
Richard Sachse pointed out: “I am excited to join Neovii and to build the new Global Scientific Department comprising regulatory, medical, and development activities. Driving Neovii to become a full-fledged pharmaceutical company is a challenging but rewarding task, and I am certain that my previous experience will highly benefit Neovii. I am enthusiastic to begin working with our in-licensing partners to provide better paths to key markets for the most innovative lines of treatments in transplantation and rare diseases.”
Neovii also appointed former Pfizer executive Alfred Doucette as Global CFO at the beginning of the year. Alfred Doucette has held several senior finance positions within Pfizer and was most recently the Commercial Director for Pfizer Consumer Healthcare for the SEE/CIS/Baltics/Greece & Cyprus, Israel and Turkey regions, bringing a huge wealth of experience in financial management.
Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.
Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.
Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Lexingtion MA, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.
For further information
For further information, please visit www.neovii.com .
For Neovii Pharmaceuticals AG
Daniela Suter, 0041 (0)44 455 84 25
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-ANDERSEN-TAX16.11.2018 15:04 | pressemeddelelse
Andersen Global Tilføjer Tax & Legal Services i Argentina
CA-GUIDEWIRE-SOFTWARE16.11.2018 14:57 | pressemeddelelse
Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations
JANSSEN16.11.2018 14:17 | pressemeddelelse
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
VERTEX-PHARMA16.11.2018 13:59 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
DIMENSION-DATA16.11.2018 09:02 | pressemeddelelse
Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation
DC-LEOSAT16.11.2018 07:02 | pressemeddelelse
FCC Grants LeoSat U.S. Market Access
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum